Biotec Pharmacon ASA has been issued two patents that cover the combination of monoclonal antibodies and yeast beta glucan for treatment of a large variety of cancers by the Japanese and the Indian Patent Offices.

Biotec Pharmacon has developed this concept together with Memorial Sloan-Kettering Cancer Center (MSKCC). Biotec Pharmacon and MSKCC are joint owners of this technology and the company has an exclusive license on MSKCC’s rights to these patents.

 

Adding these two patents to the already large portfolio of existing patents, Biotec Pharmacon has now established a strong proprietary position on this field with approved patents in the USA, Canada, Japan, India, Australia and Mexico. Several other international patent applications are still pending in major jurisdictions.

 

"These latest two patents will undoubtedly position Biotec Pharmacon in a strong situation also in the field of glucan adjuvant cancer therapy." said Svein Lien, CEO, Biotec Pharmacon ASA. "We are looking forward to receive further approvals in other countries which will then give us an almost global protection." he says.

The patents cover a pharmaceutical combination for the treatment of cancer expressing certain antigens comprising as active ingredients a complement-activating antibody capable of binding to certain antigens, and a β-glucan defined by its structure and/or its origin.